Personas / Equipo Humano

Manuel Vázquez Carrera

Buscador de publicaciones

Publicaciones

  • Manzanares-Quintela A, Restrepo-Perdomo CA, Botteri G, Castillo H, Pascual-Pastó G, Cano F, Garcia-Alvarez L, Monterrubio C, Ruiz B, Vazquez M, Suñol M, Mora J, Tornero JA, Sosnik A and Carcaboso AM.

    Tissue Compatibility of SN-38-Loaded Anticancer Nanofiber Matrices

    ADVANCED HEALTHCARE MATERIALS . 7(15): . Nº de citas: 4

    [doi:10.1002/adhm.201800255]

  • Botteri G, Salvadó L, Gumà A, Lee Hamilton D, Meakin PJ, Montagut G, Ashford MLJ, Ceperuelo-Mallafré V, Fernández-Veledo S, Vendrell J, Calderón-Dominguez M, Serra D, Herrero L, Pizarro J, Barroso E, Palomer FX and Vazquez M.

    The BACE1 product sAPPß induces ER stress and inflammation and impairs insulin signaling.

    METABOLISM-CLINICAL AND EXPERIMENTAL . 85: 59-75. Nº de citas: 31

    [doi:10.1016/j.metabol.2018.03.005]

  • Montori M, Pedreira-Casahuga R, Boyer-Díaz Z, Lassot I, García-Martínez C, Orozco A, Cebrià-Romero J, Osorio-Conles O, Chacón MR, Vendrell J, Vazquez M, Desagher S, Jimenez-Chillaron JC and Gómez-Foix AM.

    GNIP1 E3 ubiquitin ligase is a novel player in regulating glycogen metabolism in skeletal muscle.

    METABOLISM-CLINICAL AND EXPERIMENTAL . 83: 177-187. Nº de citas: 40

    [doi:10.1016/j.metabol.2018.02.005]

  • Palomer FX, Pizarro J and Vazquez M.

    Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets?

    TRENDS IN PHARMACOLOGICAL SCIENCES . 39(5): 452-467. Nº de citas: 68

    [doi:10.1016/j.tips.2018.02.010]

  • Palomer FX, Barroso E, Pizarro J, Peña L, Botteri G, Zarei M, Aguilar D, Montori M and Vazquez M.

    PPARß/d: A Key Therapeutic Target in Metabolic Disorders.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 19(3): . Nº de citas: 73

    [doi:10.3390/ijms19030913]

  • Palomer FX, Pizarro J, Barroso E and Vazquez M.

    Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus.

    TRENDS IN ENDOCRINOLOGY AND METABOLISM . 29(3): 178-190. Nº de citas: 365

    [doi:10.1016/j.tem.2017.11.009]

  • Zarei M, Barroso E, Palomer FX, Dai J, Rada P, Quesada T, Escolà-Gil JC, Cedó L, Zali MR, Molaei M, Dabiri R, Vázquez S, Pujol E, Valverde ÁM, Villarroya-Gombau F, Liu Y, Wahli W and Vazquez M.

    Hepatic regulation of VLDL receptor by PPARß/d and FGF21 modulates non-alcoholic fatty liver disease.

    molecular metabolism . 8: 117-131. Nº de citas: 80

    [doi:10.1016/j.molmet.2017.12.008]

  • Botteri G, Montori M, Gumà A, Pizarro J, Cedó L, Escolà-Gil JC, Li D, Barroso E, Palomer FX, Kohan AB and Vazquez M.

    VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells.

    Diabetologia . 60(11): 2262-2273. Nº de citas: 29

    [doi:10.1007/s00125-017-4401-5]

  • Rodríguez-Calvo R, Chanda D, Oligschlaeger Y, Miglianico M, Coumans WA, Barroso E, Tajes M, Luiken JJ, Glatz JF, Vazquez M and Neumann D.

    Small heterodimer partner (SHP) contributes to insulin resistance in cardiomyocytes.

    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE . 1862(5): 541-551. Nº de citas: 9

    [doi:10.1016/j.bbalip.2017.02.006]

  • Rodríguez-Calvo R, Tajes M and Vazquez M.

    The NR4A subfamily of nuclear receptors: potential new therapeutic targets for the treatment of inflammatory diseases.

    EXPERT OPIN THER TAR . 21(3): 291-304. Nº de citas: 95

    [doi:10.1080/14728222.2017.1279146]